Physician profile
Leonel Jorge Favio Estofan
NPI 1417339409
$8,562.84
in general payments reported to CMS, 2019-2025
30 companies · $4,380 in 2025
The $4,380 reported for 2025 was more than what 86% of Epilepsy providers received nationally (typical 2025 total: $366).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $592 · 2022: $282 · 2023: $1,330 · 2024: $1,979 · 2025: $4,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,363 · Travel and Lodging: $1,310 · Education: $16.72.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,362.90 |
| Travel and Lodging | $1,309.63 |
| Education | $16.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $1,842.90 | 2021-2025 | Visualase |
| Ucb, INC. | $1,327.52 | 2022-2025 | Briviact, Fintepla, Nayzilam |
| Abbvie INC. | $748.60 | 2022-2025 | |
| Sk Life Science, INC. | $742.52 | 2021-2025 | |
| Livanova USA, INC. | $410.78 | 2021-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Eisai INC. | $398.79 | 2023-2025 | |
| Pfizer INC. | $347.06 | 2023-2024 | |
| Jazz Pharmaceuticals INC. | $275.25 | 2024-2025 | |
| Teva Pharmaceuticals USA, INC. | $273.54 | 2023-2025 | Austedo Xr, Austedo, Ajovy |
| Catalyst Pharmaceuticals, INC. | $244.88 | 2023-2025 | Fycompa |
| Sumitomo Pharma America, INC. | $237.17 | 2023-2024 | Aptiom |
| Janssen Pharmaceuticals, INC | $228.15 | 2021-2022 | |
| Lilly USA, LLC | $218.06 | 2022-2025 | Kisunla, Amyvid, Emgality |
| Lundbeck LLC | $196.21 | 2024-2025 | Vyepti, Rexulti |
| Neurelis, INC. | $175.82 | 2023-2025 | Valtoco |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otter Pharmaceuticals, LLC | $171.30 | 2024-2025 | Sympazan |
| Neurocrine Biosciences, INC. | $170.02 | 2023 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $151.42 | 2025 | Rexulti |
| Acadia Pharmaceuticals INC | $98.34 | 2023-2025 | Daybue, Nuplazid |
| Takeda Pharmaceuticals U.S.A., INC. | $70.95 | 2024-2025 | Hyqvia |
| Argenx US, INC. | $52.44 | 2024-2025 | Vyvgart Hytrulo, Vyvgart |
| Microtransponder, INC. | $40.40 | 2023 | |
| Amylyx Pharmaceuticals, INC. | $28.43 | 2023 | Relyvrio |
| Owp Pharmaceuticals, INC. | $21.39 | 2024 | Subvenite |
| Immedica Pharma US, INC. | $19.27 | 2024 | |
| Ani Pharmaceuticals, INC. | $16.66 | 2024 | Purified Cortrophin Gel |
| Ge Healthcare | $16.11 | 2025 | |
| Aucta Pharmaceuticals, INC. | $15.16 | 2024 | Motpoly Xr |
| Zogenix INC. | $12.60 | 2021 | |
| Corium, LLC | $11.10 | 2023 | Adlarity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leonel Estofan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.